Intermolecular was founded in 2004 and is headquartered in San Jose, US

CTO

Intermolecular has an office in San Jose

San Jose, US (HQ)

3011 N 1st St

Intermolecular's revenue was reported to be $9.9 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 9.9 m |

## Gross profit (Q1, 2017) | 7 m |

## Gross profit margin (Q1, 2017), % | 70% |

## Net income (Q1, 2017) | (5.8 m) |

## EBIT (Q1, 2017) | (6 m) |

## Market capitalization (15-Aug-2017) | 44.8 m |

## Cash (31-Mar-2017) | 7.6 m |

Intermolecular's current market capitalization is $44.8 m.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 67.4 m | 47.7 m | 45.3 m | 47.3 m |

## Revenue growth, % | (29%) | (5%) | 4% | |

## Cost of goods sold | 32.5 m | 24.7 m | 19.3 m | 15.8 m |

## Gross profit | 34.9 m | 23 m | 26 m | 31.5 m |

## Gross profit Margin, % | 52% | 48% | 57% | 67% |

## Sales and marketing expense | 7.4 m | |||

## R&D expense | 28.1 m | |||

## General and administrative expense | 10.7 m | |||

## Operating expense total | 43 m | 44.1 m | 46.7 m | 47.3 m |

## EBIT | (8 m) | (21 m) | (20.7 m) | (15.9 m) |

## EBIT margin, % | (12%) | (44%) | (46%) | (34%) |

## Interest expense | 830 k | 682 k | 267 k | 173 k |

## Interest income | 173 k | |||

## Pre tax profit | (8.8 m) | (21.8 m) | (21 m) | (15.4 m) |

## Income tax expense | 17 k | 7 k | 8 k | 7 k |

## Net Income | (8.8 m) | (21.8 m) | (21 m) | (15.4 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 9.9 m | 10.9 m | 9.8 m | 11 m | 11.5 m | 14.5 m | 11.7 m | 10.6 m | 9.9 m |

## Cost of goods sold | 5.6 m | 6.2 m | 5.5 m | 4.6 m | 5 m | 4.8 m | 4.1 m | 3.5 m | 3 m |

## Gross profit | 4.3 m | 4.7 m | 4.4 m | 6.4 m | 6.5 m | 9.7 m | 7.6 m | 7.1 m | 7 m |

## Gross profit Margin, % | 43% | 43% | 44% | 58% | 56% | 67% | 65% | 67% | 70% |

## Sales and marketing expense | 1.4 m | 1.3 m | 1.3 m | 1.6 m | 1.6 m | 1.9 m | 2.1 m | 1.8 m | 1.5 m |

## R&D expense | 6.2 m | 5 m | 6.5 m | 7.2 m | 7.4 m | 6.9 m | 6.9 m | 8.5 m | 7.1 m |

## General and administrative expense | 3.1 m | 3.1 m | 3.4 m | 3.2 m | 3.2 m | 2.6 m | 2.7 m | 2.7 m | 3 m |

## Operating expense total | 10.7 m | 9.5 m | 11.2 m | 11.9 m | 12.2 m | 11.4 m | 11.7 m | 12.9 m | 11.6 m |

## EBIT | (6.7 m) | (4.8 m) | (6.9 m) | (5.6 m) | (5.8 m) | (1.7 m) | (4.1 m) | (6.9 m) | (6 m) |

## EBIT margin, % | (67%) | (44%) | (70%) | (51%) | (50%) | (12%) | (35%) | (65%) | (60%) |

## Interest expense | (179 k) | (159 k) | (134 k) | (121 k) | (52 k) | 32 k | 40 k | 51 k | 55 k |

## Interest income | 32 k | 40 k | 51 k | 55 k | |||||

## Pre tax profit | (6.9 m) | (5 m) | (7 m) | (5.7 m) | (5.8 m) | (1.7 m) | (4 m) | (6.8 m) | (5.8 m) |

## Income tax expense | 2 k | 1 k | 3 k | 2 k | 2 k | 3 k | 1 k | 3 k | 800 |

## Net Income | (6.9 m) | (5 m) | (7 m) | (5.7 m) | (5.8 m) | (1.7 m) | (4 m) | (6.8 m) | (5.8 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 72.1 m | 21.8 m | 11.7 m | 5.8 m |

## Inventories | 2.2 m | 1.8 m | 1.6 m | 1.4 m |

## Current Assets | 81.4 m | 72.2 m | 43.1 m | 32.3 m |

## PP&E | 28.5 m | 19.1 m | 15.7 m | 11 m |

## Total Assets | 124.5 m | 105.4 m | 69.7 m | 53.2 m |

## Accounts Payable | 2.2 m | 862 k | 848 k | 309 k |

## Current Liabilities | 14 m | 10.1 m | 10.2 m | 5 m |

## Total Liabilities | 8.2 m | |||

## Additional Paid-in Capital | 194.9 m | 202.1 m | 209 m | 213.3 m |

## Retained Earnings | (110.1 m) | (131.9 m) | (152.9 m) | (168.3 m) |

## Total Equity | 56.1 m | 45 m | ||

## Financial Leverage | 1.2 x | 1.2 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 41.8 m | 22.1 m | 25.6 m | 14.4 m | 3.3 m | 17.1 m | 16.4 m | 9.7 m | 7.6 m |

## Inventories | 7.3 m | 7.4 m | |||||||

## Current Assets | 76 m | 74 m | 68.9 m | 66.6 m | 43.5 m | 35.9 m | 37.9 m | 34.5 m | 32.6 m |

## PP&E | 24.5 m | 21.7 m | 18 m | 16.5 m | 16.1 m | 15.4 m | 14.4 m | 12 m | 9.8 m |

## Total Assets | 116.2 m | 111.4 m | 100.4 m | 96.2 m | 71.6 m | 66.6 m | 64 m | 57.1 m | 50 m |

## Accounts Payable | 1.1 m | 221 k | 617 k | 1.1 m | 1.8 m | 224 k | 786 k | 327 k | 746 k |

## Current Liabilities | 11.5 m | 10.4 m | 10.4 m | 10.6 m | 10.5 m | 7 m | 7.5 m | 6.5 m | 7 m |

## Additional Paid-in Capital | 198.9 m | 200.6 m | 204.6 m | 206.4 m | 207.8 m | 210.8 m | 211.7 m | 212.6 m | 214 m |

## Retained Earnings | (120.8 m) | (125.8 m) | (138.9 m) | (144.6 m) | (150.4 m) | (154.6 m) | (158.6 m) | (165.3 m) | (174.2 m) |

## Total Equity | 65.7 m | 61.8 m | 57.4 m | 56.3 m | 53.2 m | 47.3 m | 39.8 m | ||

## Financial Leverage | 1.5 x | 1.6 x | 1.2 x | 1.2 x | 1.2 x | 1.2 x | 1.3 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (8.8 m) | (21.8 m) | (21 m) | (15.4 m) |

## Depreciation and Amortization | 10.9 m | |||

## Accounts Receivable | 1.7 m | 1.1 m | ||

## Inventories | 2.2 m | 1.6 m | 1.6 m | |

## Accounts Payable | 2.2 m | (635 k) | 848 k | (493 k) |

## Cash From Operating Activities | (6.2 m) | (1.9 m) | (10.1 m) | (5.4 m) |

## Purchases of PP&E | (2.8 m) | (2.4 m) | ||

## Cash From Investing Activities | (47.7 m) | (1.2 m) | ||

## Cash From Financing Activities | (810 k) | 701 k | ||

## Interest Paid | 666 k | 9 k |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (6.9 m) | (5 m) | (7 m) | (5.7 m) | (5.8 m) | (1.7 m) | (4 m) | (6.8 m) | (5.8 m) |

## Depreciation and Amortization | 2.5 m | ||||||||

## Accounts Receivable | 425 k | ||||||||

## Inventories | 7.3 m | 7.4 m | 445 k | ||||||

## Accounts Payable | 1.1 m | 221 k | (284 k) | 1.1 m | 1.8 m | 224 k | 786 k | 327 k | 746 k |

## Cash From Operating Activities | (1.8 m) | ||||||||

## Purchases of PP&E | (927 k) | ||||||||

## Cash From Investing Activities | 5.7 m | ||||||||

## Cash From Financing Activities | 37 k | ||||||||

## Interest Paid | 191 k |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 68.6 k |

## Financial Leverage | 1.3 x |

Source: 17 public H-1B filings from Intermolecular